Your session is about to expire
← Back to Search
Gene Therapy for Non-Hodgkin's Lymphoma (NatHaLi-01 Trial)
NatHaLi-01 Trial Summary
This trial studies the safety and effectiveness of gene therapy to treat B-Cell Non-Hodgkin Lymphoma. They'll look for the best dose to use.
NatHaLi-01 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.NatHaLi-01 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have another active cancer.I take more than 20 mg of prednisone or its equivalent daily.I am on medication that suppresses my immune system.I have received approved therapy within the required time before starting the LD regimen.I haven't had cell or gene therapy recently.I had a stem cell transplant or donor lymphocyte infusion recently.My lymphoma has affected or is affecting my brain.My condition relapsed or didn't respond after 2 prior treatments.My condition is a type of non-Hodgkin lymphoma as defined by WHO.I currently have an active infection or a previously inactive infection that has become active again.I haven't taken any immune-boosting drugs recently.I have not had monoclonal antibody therapy recently.I have not had major surgery recently.I have my own stem cells stored for a treatment if I'm at high risk of long-lasting blood toxicity.I have received radiotherapy within the required time before starting the LD regimen.I have had a reaction to the drug alemtuzumab.I have a current brain or nerve condition that affects my health.I am fully active or restricted in physically strenuous activity but can do light work.I have heart problems that are not well-managed.I had a stem cell transplant using my own cells within the required time before starting LD.My B-cell NHL has returned or didn't respond to treatment and tests positive for CD20 or CD22.
- Group 1: Dose finding part
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants is the clinical trial recruiting?
"Affirmative. According to clinicaltrials.gov, this trial is currently seeking participants with an original post date of November 1st 2022 and most recent update on December 8th 2022. The study aims to recruit 80 individuals from a single medical centre."
Does this clinical trial allow for individuals aged 55 and older to participate?
"The minimum age for participation in this trial is 18, while the upper limit of eligibility is 80 years old."
Is enrollment for this experiment still open?
"Affirmative. Information on clinicaltrials.gov confirms that the recruiting process for this medical trial commenced November 1st 2022 and was most recently modified December 8th 2022. 80 patients from a single location are needed to complete it."
For whom is this clinical trial appropriate?
"This clinical trial is enrolling 80 patients between the ages of 18-80 with a b-lymphocyte diagnosis. To be eligible, participants must meet the following conditions: Relapsed or refractory (R/R) mature B-NHL per 2016 WHO criteria and positive for CD20 and/or CD22; R/R LBCL such as DLBCL, high grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements; transformed follicular lymphoma Grade 3B; an anti-CD20 antibody plus anthracycline to treat certain forms of non"
Share this study with friends
Copy Link
Messenger